Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-826 first-line pembrolizumab plus chemotherapy for persistent, recurrent, or metastatic cervical cancer
MOH_2018-10-16_003701Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing Pembrolizumab + chemotherapy with Placebo + chemotherapy (2 arms). Planned start Oct 2018; status: not yet recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on MOH_2018-10-16_003701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-16_003701.